Clinical Trial Update: Sodium Excretion of LCZ696 in Patients With Hypertension; Heart Failure and Healthy Volunteers [Phase 2]

View source ↗

Summary

Phase 2 results report on how LCZ696 (sacubitril/valsartan) affects sodium excretion in patients with hypertension, heart failure, and in healthy volunteers.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure
• Hypertension

Drugs mentioned

• Entresto (sacubitril/valsartan)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Hypertension | Phase 2 | Status: COMPLETED | Results posted: 2015-11-23